Literature DB >> 8337893

Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man.

S R Howell1, G E Husbands, J A Scatina, S F Sisenwine.   

Abstract

1. The metabolic disposition of venlafaxine has been studied in mouse, rat, dog, rhesus monkey and man after oral doses (22, 22, 2, and 10 mg/kg, and 50 mg, respectively) of 14C-venlafaxine as the hydrochloride. 2. In all species, over 85% of the administered radioactivity was recovered in the urine within 72 h, indicating extensive absorption from the GI tract and renal excretion. 3. Venlafaxine was extensively metabolized, with only 13.0, 1.8, 7.9, 0.3 and 4.7% dose appearing as parent compound in urine of mouse, rat, dog, monkey and man, respectively. The metabolite profile varied significantly among species, but primary metabolic reactions were demethylations and the conjugation of phase I metabolites. Hydroxylation of the cyclohexyl ring also occurred in mouse, rat and monkey, and a cyclic product was formed in rat and monkey. Glucuronidation was the primary conjugation reaction, although sulphate conjugates were also detected in mouse urine. 4. While no metabolite constituted more than 20% dose in any species except man, the major urinary metabolites were: mouse, N,O-didesmethyl-venlafaxine glucuronide; rat, cis-1,4-dihydroxy-venlafaxine; dog, O-desmethyl-venlafaxine glucuronide; monkey, N,N,O-tridesmethyl-venlafaxine; and man, O-desmethyl-venlafaxine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8337893     DOI: 10.3109/00498259309057023

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  22 in total

1.  Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Authors:  Alice I Nichols; Kristen Focht; Qin Jiang; Sheldon H Preskorn; Cecelia P Kane
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 2.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

Review 3.  Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.

Authors:  H J Möller; H P Volz
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

4.  Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.

Authors:  Mani Kandasamy; P Srinivas; Kala Subramaniam; Sandhya Ravi; James John; Radha Shekar; Nuggehally Srinivas; Saral Thangam
Journal:  Eur J Clin Pharmacol       Date:  2010-05-06       Impact factor: 2.953

5.  Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants.

Authors:  Kenneth F Ilett; Judith H Kristensen; L Peter Hackett; Michael Paech; Rolland Kohan; Jonathan Rampono
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 6.  Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications.

Authors:  S Caccia
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 7.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 8.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

9.  Comparison of oral absorption and bioavailablity of drugs between monkey and human.

Authors:  Win L Chiou; Paul W Buehler
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects.

Authors:  Andreas Lindauer; Timo Siepmann; Reinhard Oertel; Angelika Jung; Tjalf Ziemssen; Ulrich Jaehde; Wilhelm Kirch; Martin Siepmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.